D
Dirk Hasenclever
Researcher at Leipzig University
Publications - 142
Citations - 12749
Dirk Hasenclever is an academic researcher from Leipzig University. The author has contributed to research in topics: Lymphoma & Hodgkin's lymphoma. The author has an hindex of 35, co-authored 133 publications receiving 11700 citations.
Papers
More filters
Journal ArticleDOI
A Prognostic Score for Advanced Hodgkin's Disease
Dirk Hasenclever,Volker Diehl +1 more
TL;DR: The prognostic score developed may be useful in designing clinical trials for the treatment of advanced Hodgkin's disease and in making individual therapeutic decisions, but a distinct group of patients at very high risk could not be identified on the basis of routinely documented demographic and clinical characteristics.
Journal ArticleDOI
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial
Norbert Schmitz,Beate Pfistner,M Sextro,M. Sieber,Angelo Michele Carella,Matthias Haenel,F. Boissevain,Reinhart Zschaber,P. Müller,Hartmut Kirchner,Andreas Lohri,Susanne Decker,Bettina Koch,Dirk Hasenclever,Anthony H. Goldstone,Volker Diehl +15 more
TL;DR: High-dose BEAM and transplantation of haemopoietic stem cells improves freedom from treatment failure in patients with chemosensitive first relapse of Hodgkin's disease irrespective of length of initial remission.
Journal ArticleDOI
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
Michael Hummel,Stefan Bentink,Hilmar Berger,Wolfram Klapper,Swen Wessendorf,Thomas F. E. Barth,Heinz Wolfram Bernd,Sergio Cogliatti,Judith Dierlamm,Alfred C. Feller,Martin-Leo Hansmann,Eugenia Haralambieva,Lana Harder,Dirk Hasenclever,Michael Kühn,Dido Lenze,Peter Lichter,José I. Martín-Subero,Peter Möller,Hans Konrad Müller-Hermelink,German Ott,Reza Parwaresch,Christiane Pott,Andreas Rosenwald,Maciej Rosolowski,Carsten Schwaenen,Benjamin Stürzenhofecker,Monika Szczepanowski,Heiko Trautmann,Hans Heinrich Wacker,Rainer Spang,Markus Loeffler,Lorenz Trümper,Harald Stein,Reiner Siebert +34 more
TL;DR: The molecular definition of Burkitt's lymphoma clarifies and extends the spectrum of the WHO criteria for Burkitt’s lymphoma.
Journal ArticleDOI
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease
Volker Diehl,Jeremy Franklin,Michael Pfreundschuh,B. Lathan,Ursula Paulus,Dirk Hasenclever,Hans Tesch,Richard Herrmann,Bernd Dörken,Hans Konrad Müller-Hermelink,Eckhardt Dühmke,Markus Loeffler +11 more
TL;DR: Investigation of three combinations of chemotherapy for advanced Hodgkin's disease found increased-dose BEACOPP resulted in better tumor control and overall survival than did COPP-ABVD and standard BEACopP.
Journal ArticleDOI
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL
Michael Pfreundschuh,Lorenz Trümper,Marita Kloess,Rudolf Schmits,Alfred C. Feller,Christian Rübe,Christian Rudolph,Marcel Reiser,Dieter K. Hossfeld,Hartmut Eimermacher,Dirk Hasenclever,Norbert Schmitz,Markus Loeffler +12 more
TL;DR: CHOP-14 should be considered the new standard chemotherapy regimen for patients ages 60 or older with aggressive lymphoma due to its favorable efficacy and toxicity profile.